• Cash Balance: $6.3 million at the end of the quarter.
• Cash Used in Operations: $3 million for the three months and $7.8 million for the nine months ended September 2024.
• Net Loss: $1.8 million or 5 per share for the three months; $8.3 million or 22 per share for the nine months ended September 30, 2024.
• Net Loss Comparison: $5.1 million or 15 per share for the three months; $17 million or 50 per share for the nine months ended September 30, 2023.
• Operating Burn Reduction: Nearly 60% reduction from the same time last year.

• Warning! GuruFocus has detected 2 Warning Signs with INKT.

Release Date: November 14, 2024

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

• MiNK Therapeutics Inc (NASDAQ:INKT) has made significant advancements in their iNKT cell therapy platform, which is poised to be scalable and transformative for treating solid tumor cancers and other immune-related diseases.
• The company has achieved a 60% reduction in operating burn compared to the previous year, demonstrating improved operational efficiency.
• MiNK Therapeutics Inc (NASDAQ:INKT) has strengthened its leadership team by adding Dr. Robert Cadle, whose experience in public health and biodefense brings strategic value.
• Promising early data from the phase two trial of their lead program, agent 797, in second-line advanced gastric cancer shows potential efficacy compared to existing treatments.
• The company has formed a collaboration with Autonomous Therapeutics to enhance clinical outcomes using cutting-edge technology, combining encrypted RNA technology with their T cell therapy.

Negative Points

• MiNK Therapeutics Inc (NASDAQ:INKT) has a limited cash balance of $6.3 million, which may pose challenges in sustaining long-term operations without additional funding.
• The company faces risks and uncertainties related to clinical development, regulatory approvals, and commercial plans, as highlighted in their forward-looking statements.
• Enrollment in the phase two gastric cancer study is ongoing, and while progressing, it is not yet complete, which may delay data updates and potential commercialization.
• Despite advancements, the company is still in the early stages of clinical trials for several programs, including the graft versus host disease program, which may take time to yield results.
• The financials indicate a net loss for the quarter, reflecting ongoing challenges in achieving profitability amidst high R&D and operational expenses.

Q & A Highlights

Q: How is enrollment progressing in the phase two gastric study, and what should we expect from the data update in early 2025? Also, what factors are driving the decline in R&D expenses? A: Enrollment in the phase two gastric study is progressing rapidly, with the trial being close to halfway done. The study started at the end of Q1 2024, and some patients have mature data. Updates will be presented at a conference in early 2025. The decline in R&D expenses is due to increased manufacturing efficiencies, particularly in reducing the cost of starting materials for cell manufacturing, allowing for significant financial impact while advancing scientific endeavors. - Jennifer Buell, President, CEO, Director

Q: Can you provide more details on the trial design and endpoints for the graft versus host disease program? A: The trial targets patients undergoing stem cell transplantation with elevated risk factors for acute GVHD. Eligibility includes patients receiving allogenic stem cells with identified risk markers. The control arm will likely involve standard care corticosteroids. More details, including trial leadership and design, will be shared in the next earnings call. - Jennifer Buell, President, CEO, Director

Q: What are the main advancements in the clinical programs and preclinical progress? A: The lead program, agent 797, is in a phase two trial for advanced gastric cancer, showing promising efficacy signals. Data presented at the Society for Immune Therapy of Cancer highlighted the potential of agent 797 to enhance immune checkpoint inhibitors and bispecific engagers. Additionally, novel frame TCR iNKT cell therapy shows potential for treating frame-expressing tumors. - Jennifer Buell, President, CEO, Director

Q: What is the significance of the collaboration with Autonomous Therapeutics? A: The collaboration aims to combine encrypted RNA technology with Mink's T cell therapy to target metastatic cancer cells more effectively. This partnership represents a significant step forward in enhancing clinical outcomes and delivering better patient care through cutting-edge technology. - Jennifer Buell, President, CEO, Director

Q: How has the financial performance been for the quarter, and what are the future financial priorities? A: Mink ended the quarter with a cash balance of $6.3 million, with reduced cash usage in operations compared to the previous year. The net loss for the quarter was $1.8 million. The company remains focused on financial discipline and strategic initiatives to support growth and development of the iNKT cell therapy platform. - Christine Klaskin, Principal Financial and Accounting Officer

For the complete transcript of the earnings call, please refer to the full earnings call transcript.